Wednesday 20 May 2026
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Conference News
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • EU Commission welcomes research infrastructure legal framework accord

EU Commission welcomes research infrastructure legal framework accord

8 June 2009

The European Commission has welcomed the agreement reached at the end of May by the Council, on its proposal for a regulation for a community  legal framework for European Research Infrastructures Consortium  (ERIC). The regulation will make it easier to set up European Research  Infrastructures, such as cutting edge installations to test  technologies for carbon dioxide capture and storage, data banks in  genomics or state-of-the-art large super computers.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news






Today's issue

Scene set for Scenic to take ‘top-notch science’ into the clinic
Biotechnology
Scene set for Scenic to take ‘top-notch science’ into the clinic
20 May 2026
Pharmaceutical
US State price-setting boards create more questions than answers
20 May 2026
Pharmaceutical
Chiesi appoints Maria Paola Chiesi as first female chair
20 May 2026
Biotechnology
UK launches national framework to strengthen advanced therapy clinical trials
20 May 2026
Pharmaceutical
Remepy posts strong Phase IIa results for Hybridopa
20 May 2026
Pharmaceutical
Pfizer advances pediatric pneumococcal vaccine program
20 May 2026
Biosimilars
MS Pharma wins investment from Olayan Financing
20 May 2026


Company Spotlight

Scenic Biotech
A biotech based in Amsterdam, specializing in "modifier therapy"—an approach that targets genes other than the primary disease-causing one, to restore cellular balance.




The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom


  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising
  • Company News Directory


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin
Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze